Dimensional Fund Advisors LP Cuts Stake in Chemours Company (The) (CC)

Dimensional Fund Advisors LP lessened its holdings in Chemours Company (The) (NYSE:CC) by 1.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 699,745 shares of the specialty chemicals company’s stock after selling 7,184 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Chemours Company (The) worth $26,524,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Financial Architects Inc raised its stake in shares of Chemours Company (The) by 1,230.3% in the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after acquiring an additional 2,719 shares during the period. Acrospire Investment Management LLC raised its stake in shares of Chemours Company (The) by 3.4% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock valued at $117,000 after acquiring an additional 100 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Chemours Company (The) by 2,138.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after acquiring an additional 2,973 shares during the period. Smithfield Trust Co. raised its stake in shares of Chemours Company (The) by 521.4% in the 2nd quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after acquiring an additional 4,020 shares during the period. Finally, Alps Advisors Inc. purchased a new position in shares of Chemours Company (The) in the 2nd quarter valued at $202,000. 72.99% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/05/dimensional-fund-advisors-lp-cuts-stake-in-chemours-company-the-cc.html.

In other Chemours Company (The) news, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP David C. Shelton sold 13,337 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total transaction of $646,577.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,142 shares of company stock valued at $3,953,265. 1.14% of the stock is owned by company insiders.

CC has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 price target for the company in a report on Friday, July 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $50.00 price target (up from $48.00) on shares of Chemours Company (The) in a report on Thursday, July 13th. Citigroup Inc. raised their price target on shares of Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 4th. J P Morgan Chase & Co raised their price target on shares of Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a report on Friday, August 4th. Finally, UBS AG raised shares of Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price target for the company from $36.00 to $50.00 in a report on Monday, August 7th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $53.88.

Shares of Chemours Company (CC) opened at $52.16 on Friday. The firm has a market cap of $9,639.22, a price-to-earnings ratio of 18.50, a P/E/G ratio of 0.93 and a beta of 3.59. Chemours Company has a fifty-two week low of $16.39 and a fifty-two week high of $58.08. The company has a current ratio of 1.97, a quick ratio of 1.48 and a debt-to-equity ratio of 7.09.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.11. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.59 billion. Chemours Company (The) had a net margin of 4.86% and a return on equity of 155.80%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $0.61 EPS. equities analysts anticipate that Chemours Company will post 3.63 earnings per share for the current year.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

What are top analysts saying about Chemours Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Company (The) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit